Pharming Group N.V.
http://www.pharming.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharming Group N.V.
Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
No Rest For The Pneumococcal Work Group: CDC Committee Readies For Merck’s V116
Merck’s 21-valent pneumococcal conjugate vaccine for older adults could see US FDA approval in H1 2024, opening up another level of complexity for the CDC’s vaccine recommendations.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Transgenics
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice